DNA was isolated from 100 mL of apheresis product or 200 µL of peripheral blood (PB) isolated by centrifugation on Ficoll-Hypaque (Lymphoprep Axis-Shield, PoC AS, Oslo, Norway) from 3 mL of PB collected into EDTA. A QIAamp DNA Blood Mini Kit (QIAgen, Germany) was used according to the manufacturer's instructions. The concentration and purity of DNA were determined by absorbance readings at a wavelength of 260 nm and a ratio of 260/280 nm, respectively, with Nanodrop, ND-1000 (Wilmington, DE, USA). Allelic variants were genotyped by allelic discrimination polymerase chain reaction (PCR) assays using TaqMan ® Genotyping Assays (PE Applied Biosystems, Foster City, CA, USA). Specific primers and FAM™ and VIC™ dye-labeled probes were ordered by either Custom Taqman® SNP Genotyping Assays using File Builder Software v3.0 or Taqman® SNP Assays Applied Biosystems service. PCR reactions were carried out in 96-well plates at a final volume of 12.5 mL containing 50 ng of genomic DNA, 6.25 mL 1 x Genotyping Master Mix and 0.25 mL 1 x SNP Assay. Negative controls were also run. PCR reactions were performed on an ABI Prism 7500 FAST Real Time PCR System (Applied Biosystems, Foster City, CA, USA). Conditions were as follows: initial denaturation at 95ºC for 10 min, 45 cycles of denaturation (93ºC for 15 sec) followed by annealing and elongation (60ºC for 1 min). The software determined the fluorescent signal from the FAM™ and/or VIC™ labeled probe.
RNA isolation and gene expression analysis
Total RNA was isolated from 100 mL of apheresis product using a RNeasy Blood Mini Kit (Qiagen, Valencia, CA), and from 800 mL of a leukocyte concentrate obtained by a density gradient separation on Ficoll-Hypaque from 3 mL of PB collected into EDTA using TRIzol (Invitrogen Ltd, Paisley, UK), both according to the manufacturers' protocol. RNA isolated was treated twice with DNase I using the RNaseFree DNase kit (QIAgen, Germany) for 20 min. RNA integrity was checked on a 2% agarose gel. The concentration, purity and quality of total RNA were determined by spectrophotometry using Nanodrop ND-1000. Total RNA (1 µg) from each sample was reverse-transcribed using the iScript TM cDNA Synthesis kit (Bio-Rad). Real-time PCR analysis was carried out using an iCycler (Strategene Mx 3005P™). Reactions were done in a 25 mL volume containing cDNA generated from 10 ng of original RNA template, 12.5 mL of iQTM SYBR Green Supermix (BioRad) and 300 nM each of specific forward and reverse primers. The primer sequences were as follows: ACTBFw/ACTBRv: 5'ggacttcgagcaagagatgg3'/5'agcactgtgttggcgtacag3', VCAM1Fw/VCAM1Rv: 5'aaaagcggagacaggagaca/3'agcacgagaagctcaggaga, CD44Fw/CD44Rv: 5 ' g g g t c t g c c a g a g g c c c a g a 3 ' / 5 ' c a g c c t c t a c c t g t c g c c c c a 3 ' , CSF3RFw/CSF3RRv: 5'ggaagacagcggacggat3'/5'tctgagaagaccaccggagtg3', CXCL12Fw/CXCL12Rv: 5'actctccgtcagccgcattg3'/5'aatcggcatgggcatctgtag3', CXCR4Fw.1/CXCR4Rv.1: 5'tgtccattcctttgcctcttt3'/5'agaggaggtcggccactgaca3', CXCR4Fw.2/CXCR4Rv.2: 5'ggaggggatcagtatatacac3'/5'acaatgccagttaagaa3'; for b-actin, VCAM1, CD44, CSF3R, CXCL12 and CXCR4 variant1 and variant 2, respectively. Matching oligonucleotide primers were designed using Oligo v 6.89 software (Medprobe). The amplification protocol used was as follows: initial denaturation and enzyme activation for 3 min 30 sec at 95 ºC, followed by 40 cycles of 95 ºC for 15 sec, optimal annealing temperature of 68ºC for 15 sec and elongation at 72ºC for 30 sec. Each assay was done in duplicate. For normalization of cDNA loading, all samples were run in parallel with the housekeeping gene b-actin. Relative mRNA expression was determined using the 2 (-DDCt) method and calibrating each SNP with the genotype at steady state. Online Supplementary Table S1 . Main characteristics of group 1 donors (the group receiving G-CSF) and of group 2 donors (steady state). 
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